at 8 weeks and every 8 weeks thereafter, participants were assessed based on A1C response to determine if a dose adjustment was warranted
If you're on a GLP-1 receptor agonist - semaglutide, tirzepatide, or another GLP-1-class medication - and you're experiencing meaningful weight loss, here's what the published evidence and clinical consensus suggest a responsible musculoskeletal protection plan looks like
Its a protein-rich, fiber-filled dinner that aligns beautifully with GLP-1focused eating habits
Keep track of nausea levels, energy, appetite, digestion, and any unusual symptoms
Microscopic examination of mouse colonic tissue reveals reduced inflammatory cell infiltration, maintained crypt morphology, and fewer surface defects in the PYY group compared to controls (Supplementary Fig
384, no